Accelerate Diagnostics, Inc.
United StatesFDA applicant, unverified
Accelerate Diagnostics, Inc. is a medical device manufacturer, with 10 devices listed in FDA GUDID and FDA 510(k) (FDA Class II) and 4 FDA recalls as of 21 Nov 2026.
- Devices
- 10
- FDA recalls
- 42 ongoing
Registry facts
- Registries
- FDA GUDID 8
- FDA 510(k) 2
- Device classes
- FDA Class II 10
- FDA recalls
- Identifiers
- DUNS 186328670
At a glance
Market reach
- United States
- FDA recalls
What Accelerate Diagnostics, Inc. makes
The company manufactures nucleic acid-based in vitro diagnostic (IVD) systems and kits designed to detect multiple bloodstream pathogens, including those used for identification and antimicrobial susceptibility testing. These products integrate nucleic acid amplification with mass spectrometry to identify bacteria and fungi in bloodstream infections, alongside quality control tests for blood culture systems. The portfolio includes both standalone kits and systems for laboratory use, supporting rapid pathogen detection and resistance profiling.
The devices fall under FDA Class II regulation and are authorised via 510(k) clearances and the Unique Device Identifier (UDI) system. They are listed in the FDA’s regulatory databases, reflecting compliance with US medical device requirements.
Catalogue
- Regimes: De Novo Registry: GUDID
- Regimes: De Novo Registry: GUDID
- Regimes: De Novo Registry: GUDID
- Regimes: De Novo Registry: GUDID
- Regimes: De Novo Registry: GUDID
- Registry: GUDID
- Regimes: De Novo Registry: GUDID
- Regimes: De Novo Registry: GUDID
- Regimes: 510(k) Registry: 510(k)
Accelerate Arc System Ref K240854
Regimes: 510(k) Registry: 510(k)
Company details
- DUNS number
- 186328670
FDA recalls
FDA recall records list 4 recalls initiated by Accelerate Diagnostics, Inc., the earliest on 2017-03-13 and the most recent on 2022-10-17. By recorded status: 2 ongoing and 2 terminated. The reasons filed fall into these groups: performance or accuracy and manufacturing or quality process. A recall is often a precaution started by the manufacturer, and a count of records is not a verdict on a company.
Recalls initiated per year
- 2017 1
- 2018 1
- 2019 0
- 2020 0
- 2021 0
- 2022 2
- 2023 0
- 2024 0
- 2025 0
- 2026 0
2022
- 17 Oct 2022 Z-0345-2023 Class II Ongoing Due improperly formulated and released bulk lot of fluorescence in situ hybridization (FISH) probes resulting in false positive identification results for Staphylococcus aureus and Streptococcus spp.
Full distribution text
- 17 Oct 2022 Z-0346-2023 Class II Ongoing Due improperly formulated and released bulk lot of fluorescence in situ hybridization (FISH) probes resulting in false positive identification results for Staphylococcus aureus and Streptococcus spp.
Full distribution text
- 17 Oct 2022 Z-0345-2023 Class II Ongoing Due improperly formulated and released bulk lot of fluorescence in situ hybridization (FISH) probes resulting in false positive identification results for Staphylococcus aureus and Streptococcus spp.
2018
- 14 Mar 2018 Z-1529-2018 Class II Terminated The kits may produce an elevated rate of false positive calls for the Staphylococcus aureus identification probe (SAU).
2017
- 13 Mar 2017 Z-1065-2019 Class II Terminated Rare isolates of Enterobacteriaceae may generate a susceptible meropenem Minimum Inhibitory Concentration (MIC) using the affected device and a resistant result by broth microdilution. In order to mitigate any risk associated with these rare isolates, the firm has implemented an Expert Rule that suppresses the meropenem result for isolates that display a profile consistent with those that generated a false-susceptible result. The firm has responded to this risk by implementing a set of suppression rules, in a software update, to prevent incorrect results.
Full distribution text
- 13 Mar 2017 Z-1065-2019 Class II Terminated Rare isolates of Enterobacteriaceae may generate a susceptible meropenem Minimum Inhibitory Concentration (MIC) using the affected device and a resistant result by broth microdilution. In order to mitigate any risk associated with these rare isolates, the firm has implemented an Expert Rule that suppresses the meropenem result for isolates that display a profile consistent with those that generated a false-susceptible result. The firm has responded to this risk by implementing a set of suppression rules, in a software update, to prevent incorrect results.
Frequently asked questions
How many devices does Accelerate Diagnostics, Inc. have in the registry?
The registry currently lists 10 devices for Accelerate Diagnostics, Inc.. Devices recorded under merged duplicate company entries are counted once.
Which registries list Accelerate Diagnostics, Inc.'s devices?
Among its 10 most recently registered devices, Accelerate Diagnostics, Inc. has devices listed in FDA 510(k) (2 devices) and FDA GUDID (8 devices). A device can be listed in more than one registry, so these counts overlap.
What risk classes do Accelerate Diagnostics, Inc.'s devices fall under?
Among its 10 most recently registered devices, the classes recorded for Accelerate Diagnostics, Inc.'s devices are Class II. Each device page shows its own class and authorisation.
Are there FDA recall records for Accelerate Diagnostics, Inc.?
FDA recall records list 4 recalls initiated by Accelerate Diagnostics, Inc., the most recent initiated on 17 Oct 2022. 2 of them are recorded as ongoing. A recall is often a precaution started by the manufacturer; the records say nothing about the company's overall record.
What are the newest devices from Accelerate Diagnostics, Inc. in the registry?
The most recently registered devices listed for Accelerate Diagnostics, Inc. include Accelerate Pheno™ System 10301008, Accelerate PhenoTest® BC AST QC test 10107158, Accelerate PhenoTest BC ID QC test 10105158 and Accelerate PhenoTest™ BC Kit 10101018.